Ovarian Cancer Screening

Variant: 1 Adult. Ovarian cancer screening. Postmenopausal. Average risk.

Procedure	Appropriateness Category	Relative Radiation Level
US color Doppler ovaries	Usually Not Appropriate	O
US pelvis transabdominal	Usually Not Appropriate	O
US pelvis transvaginal	Usually Not Appropriate	O
MRI pelvis without and with IV contrast	Usually Not Appropriate	O
MRI pelvis without IV contrast	Usually Not Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT skull base to mid-thigh	Usually Not Appropriate	☢☢☢☢

Variant: 2 Adult. Ovarian cancer screening. Premenopausal. Average risk.

Procedure	Appropriateness Category	Relative Radiation Level
US color Doppler ovaries	Usually Not Appropriate	O
US pelvis transabdominal	Usually Not Appropriate	O
US pelvis transvaginal	Usually Not Appropriate	O
MRI pelvis without and with IV contrast	Usually Not Appropriate	O
MRI pelvis without IV contrast	Usually Not Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT skull base to mid-thigh	Usually Not Appropriate	☢☢☢☢

Variant: 3 Adult. Ovarian cancer screening. Premenopausal. High risk.

Procedure	Appropriateness Category	Relative Radiation Level
US color Doppler ovaries	May Be Appropriate	O
US pelvis transabdominal	May Be Appropriate	O
US pelvis transvaginal	May Be Appropriate	O
MRI pelvis without and with IV contrast	Usually Not Appropriate	O
MRI pelvis without IV contrast	Usually Not Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT skull base to mid-thigh	Usually Not Appropriate	☢☢☢☢

Variant: 4 Adult. Ovarian cancer screening. Postmenopausal. High risk.

Procedure	Appropriateness Category	Relative Radiation Level
US color Doppler ovaries	May Be Appropriate	O
US pelvis transabdominal	May Be Appropriate	O
US pelvis transvaginal	May Be Appropriate	O
MRI pelvis without and with IV contrast	Usually Not Appropriate	O
MRI pelvis without IV contrast	Usually Not Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT skull base to mid-thigh	Usually Not Appropriate	☢☢☢☢

Panel Members

Aradhana M. Venkatesan, MD^a; Aoife Kilcoyne, MD^b; Esma A. Akin, MD^c; Linus Chuang, MD^d; Nicole M. Hindman, MD^e; Chenchan Huang, MD^f; Carolyn Kay McCourt, MD^g; Gaiane M. Rauch, MD, PhD^h; Maryam Sattari, MD, MSⁱ; Nancy Schoenborn, MD, MHS^j; David Schultz, MD^k; Madeleine Sertic, MB, BCh^l; William Small Jr., MD^m; Erica B. Stein, MDⁿ; Krista Suarez-Weiss, MD^o; Stella K. Kang, MD, MS^p.

Summary of Literature Review

Introduction/Background

Discussion of Procedures by Variant

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
A. CT abdomen and pelvis with IV contrast

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
B. CT abdomen and pelvis without and with IV contrast

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
C. CT abdomen and pelvis without IV contrast

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
D. FDG-PET/CT skull base to mid-thigh

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
E. MRI pelvis without and with IV contrast

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
F. MRI pelvis without IV contrast

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
G. US color Doppler ovaries

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
H. US pelvis transabdominal

Variant 1: Adult. Ovarian cancer screening. Postmenopausal. Average risk.
I. US pelvis transvaginal

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
A. CT abdomen and pelvis with IV contrast

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
B. CT abdomen and pelvis without and with IV contrast

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
C. CT abdomen and pelvis without IV contrast

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
D. FDG-PET/CT skull base to mid-thigh

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
E. MRI pelvis without and with IV contrast

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
F. MRI pelvis without IV contrast

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
G. US color Doppler ovaries

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
H. US pelvis transabdominal

Variant 2: Adult. Ovarian cancer screening. Premenopausal. Average risk.
I. US pelvis transvaginal

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
A. CT abdomen and pelvis with IV contrast

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
B. CT abdomen and pelvis without and with IV contrast

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
C. CT abdomen and pelvis without IV contrast

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
D. FDG-PET/CT skull base to mid-thigh

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
E. MRI pelvis without and with IV contrast

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
F. MRI pelvis without IV contrast

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
G. US color Doppler ovaries

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
H. US pelvis transabdominal

Variant 3: Adult. Ovarian cancer screening. Premenopausal. High risk.
I. US pelvis transvaginal

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
A. CT abdomen and pelvis with IV contrast

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
B. CT abdomen and pelvis without and with IV contrast

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
C. CT abdomen and pelvis without IV contrast

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
D. FDG-PET/CT skull base to mid-thigh

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
E. MRI pelvis without and with IV contrast

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
F. MRI pelvis without IV contrast

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
G. US color Doppler ovaries

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
H. US pelvis transabdominal

Variant 4: Adult. Ovarian cancer screening. Postmenopausal. High risk.
I. US pelvis transvaginal

Summary of Highlights

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

Gender Equality and Inclusivity Clause

The ACR acknowledges the limitations in applying inclusive language when citing research studies that predates the use of the current understanding of language inclusive of diversity in sex, intersex, gender, and gender-diverse people. The data variables regarding sex and gender used in the cited literature will not be changed. However, this guideline will use the terminology and definitions as proposed by the National Institutes of Health.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria^® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢☢	0.1-1 mSv	0.03-0.3 mSv
☢☢☢	1-10 mSv	0.3-3 mSv
☢☢☢☢	10-30 mSv	3-10 mSv
☢☢☢☢☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

References

1.	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12-49.
2.	Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009; 361(2):170-177.
3.	Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4.	Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11):1329-1333.
5.	US Preventive Services Task Force, Owens DK, Davidson KW, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 322(7):652-665, 2019 08 20.
6.	Nebgen DR, Lu KH, Bast RC Jr. Novel Approaches to Ovarian Cancer Screening. [Review]. Curr Oncol Rep. 21(8):75, 2019 07 26.
7.	Peres LC, Cushing-Haugen KL, Kobel M, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst 2019;111:60-68.
8.	Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA: a Cancer Journal for Clinicians. 68(4):284-296, 2018 07.
9.	Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010.
10.	Forstner R. Early detection of ovarian cancer. Eur Radiol. 30(10):5370-5373, 2020 Oct.
11.	Pickhardt PJ, Hanson ME. Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. Radiology 2010;257:144-50.
12.	Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-2303.
13.	Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.[Erratum appears in Lancet. 2016 Mar 5;387(10022):944], [Erratum appears in Lancet. 2016 Mar 5;387(10022):944; PMID: 28832000]. Lancet. 387(10022):945-956, 2016 Mar 05.
14.	Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999; 353(9160):1207-1210.
15.	Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008; 18(3):414-420.
16.	Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 2013;119:3454-61.
17.	Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-340.
18.	Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005; 23(31):7919-7926.
19.	van Nagell JR, Jr., Miller RW, DeSimone CP, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 2011;118:1212-21.
20.	Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 2013;130:674-81.
21.	Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009; 113(4):775-782.
22.	Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer. 2006; 16 Suppl 1:54-59.
23.	Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006; 100(1):20-26.
24.	Stirling D, Evans DG, Pichert G, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 2005;23:5588-96.
25.	van der Velde NM, Mourits MJ, Arts HJ, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer. 2009; 124(4):919-923.
26.	Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013;31:49-57.
27.	Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology. 35(13):1411-1420, 2017 May 01.
28.	Lacey JV, Jr., Greene MH, Buys SS, et al. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol. 2006; 108(5):1176-1184.
29.	Lai T, Kessel B, Ahn HJ, Terada KY. Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. J Gynecol Oncol 2016;27:e41.
30.	National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Committee on National Statistics; Committee on Measuring Sex, Gender Identity, and Sexual Orientation. Measuring Sex, Gender Identity, and Sexual Orientation. In: Becker T, Chin M, Bates N, eds. Measuring Sex, Gender Identity, and Sexual Orientation. Washington (DC): National Academies Press (US) Copyright 2022 by the National Academy of Sciences. All rights reserved.; 2022.
31.	American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.

Disclaimer

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.